Physician profile
Ronald E Devine
NPI 1174637532
$3,628.69
in general payments reported to CMS, 2019-2025
21 companies · $202 in 2025
The $202 reported for 2025 was more than what a typical Infectious Disease provider received nationally (typical 2025 total: $187).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,960 · 2020: $107 · 2021: $288 · 2022: $288 · 2023: $360 · 2024: $422 · 2025: $202.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $940 · Education: $44.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $939.54 |
| Education | $44.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Paratek Pharmaceuticals, INC. | $1,871.62 | 2019-2024 | Nuzyra |
| Abbvie INC. | $373.04 | 2021-2025 | Avycaz, Dalvance, Mavyret |
| Astellas Pharma US INC | $287.92 | 2022-2024 | Cresemba |
| Merck Sharp & Dohme LLC | $245.43 | 2019-2025 | Dificid, Zerbaxa, Recarbrio |
| Allergan, INC. | $151.69 | 2019-2020 | |
| Viiv Healthcare Company | $120.12 | 2020-2025 | Apretude, Cabenuva |
| Melinta Therapeutics, LLC | $102.81 | 2024-2025 | Kimyrsa, Rezzayo, Orbactiv |
| La Jolla Pharmaceutical Company | $78.66 | 2021-2024 | Xerava |
| Cumberland Pharmaceuticals, INC. | $58.73 | 2021-2023 | Vibativ |
| Insmed, INC. | $50.10 | 2021-2024 | Arikayce |
| Aimmune Therapeutics, INC. | $49.38 | 2025 | Vowst |
| Gilead Sciences, INC. | $47.04 | 2022-2024 | |
| Napo Pharmaceuticals INC | $37.59 | 2021-2022 | |
| Mayne Pharma Commercial LLC | $30.35 | 2021 | |
| Shionogi INC | $23.33 | 2021 |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dynavax Technologies Corporation | $20.43 | 2022 | |
| Theratechnologies INC. | $19.68 | 2023 | Trogarzo, Egrifta |
| Tetraphase Pharmaceuticals, INC. | $17.86 | 2019 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $15.78 | 2024 | Xifaxan, Trulance |
| Janssen Scientific Affairs, LLC | $14.22 | 2019 | |
| Hydrofera LLC | $12.91 | 2023 | Hydrofera Blue |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ronald Devine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.